High-dose IL-2 priming amplifies the number of tumor-specific naïve CD8+ T cells without clonal exhaustion and results in the generation of potent tumor-reactive CTLs with capacity to overcome tumor-derived immune suppression. This evidence concerns the gene CD8A and neoplasm.